I will qualify what is below by saying that the entity appears to be freshly organized and/or the below trail may lead to a different entity. However, the closest I can come to receptor in a name of an entity in Washington is a very small shop (I suspect). Hoping it is unrelated; and not just a corporation that was formed by the LLC listed below.
That said....
Searching the Secretary of State (Washington) website for receptor (http://www.sos.wa.gov/corps/search_detail.aspx?ubi=603397704) leads to this:
FC RECEPTOR LLC
UBI Number 603397704
Category LLC
Active/Inactive Inactive
State Of Incorporation WA
WA Filing Date 04/25/2014
Expiration Date 04/30/2015
Inactive Date 08/03/2015
Duration Perpetual
Registered Agent Information
Agent Name RONALD DUDEK
Address 300 211TH PLACE SE
City SAMMAMISH
State WA
ZIP 98074
Special Address Information
Address
City
State
Zip
Governing Persons
Title Name Address
Member Dudek, Ronald 300 211th Place SE
SAMMAMISH, WA 98074
Member Sundberg, Eric 300 211th Place SE
SAMMAMISH, WA 98074
A search of Ronald Dudek, (https://www.linkedin.com/pulse/challenges-car-cell-commercialization-webinar-ronald-p-dudek) leads to this:
Ronald P. Dudek offers the unique view of a seasoned entrepreneur who founded two CAR T cell companies. His most recent venture, Restoration Oncology, Inc. (ROI), was focused on commercializing the Memorial Sloan Kettering Cancer Center CAR T cell technology. Recently, Mr. Dudek was Vice President, Commercial Strategy, at Juno Therapeutics, Inc., whose lead product, JCAR-15, was Restoration Oncology’s lead product, ROI-19.
A google search on Eric Sundberg leads nowhere.
Here is something about Eric Sunberg, copy and pasted couldn't get link to work
The HyGly technology originates in
the laboratory of Eric J. Sundberg, an
associate professor of medicine at the
University of Maryland School of Medicine.
Sundberg is chief scientific officer
of Glycocept. Dudek, who has 25 years
of experience working in biotechnology
and immunology research, most recently
served as vice president of commercial
strategy at Juno Therapeutics.
Dudek says Glycocept is currently in
the in-vitro stage of data-gathering and is
seeking funding for animal studies. The
company plans to partner with pharmaceutical
companies and other businesses
producing antibodies to develop HyGly
versions of existing antibodies. Dudek
tells DDNews that Glycocept will also
work to develop proprietary HyGly antibody
drugs, such as biobetter versions of
blockbuster antibody drugs with soonto-expire
patents.
